Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
Status:
Completed
Trial end date:
2017-05-23
Target enrollment:
Participant gender:
Summary
This study will determine the safety profile, tolerability, and maximum tolerated dose (MTD)
and disease response of Ixazomib administered orally in participants with relapsed and/or
refractory multiple myeloma.